Quinidine, Serum or Plasma
Use
This Class 1A drug is useful in both supraventricular and ventricular arrhythmias. It major uses are to maintain sinus rhythm after conversion of atrial flutter or fibrillation, to prevent ventricular tachycardia, and for long-term prophylaxis in patients with AV nodal reentrant tachycardia and automatic atrial tachycardia. Quinidine also has been used to prevent symptomatic premature supraventricular and ventricular complexes. Because it slows conduction and prolongs the refractory period of the accessory pathway and suppresses automaticity of ectopic pacemakers, quinidine may prevent recurrences of paroxysmal supraventricular tachycardia caused by reentry over a concealed pathway or AV reciprocating tachycardia associated with the Wolff-Parkinson-White syndrome. It also may slow the ventricular response to atrial flutter or fibrillation in the preëxcitation syndrome. Quinidine is often preferred to procainamide for long-term therapy because elevated antinuclear antibody titers and drug-induced lupus are common during prolonged therapy with procainamide.
Special Instructions
Optimal resampling time after a change in dosage is one to two days. The biologic half-life is about six to eight hours. Serum digoxin concentrations should be measured before initiation of quinidine therapy and again in four to six days. The volume and storage time of specimens should be carefully monitored as it affects drug levels due to absorption.
Limitations
Renal failure can prolong the apparent half-life of quinidine, potentially through the accumulation of fluorescent metabolites. Severe heart failure and liver disease also prolong the half-life. Concomitant administration of phenytoin increases hepatic metabolism, decreasing the half-life and serum quinidine concentrations. Clearance may be diminished in the elderly. Use of gel-barrier tubes can slow drug absorption, leading to decreased drug levels, which may be clinically significant.
Methodology
Immunoassay (IA)
Biomarkers
LOINC Codes
- 6694-4
- 6694-4
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL
Container
Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube.
Collection Instructions
Transfer separated serum or plasma to a plastic transport tube. Peak: quinidine sulfate: 11/2 hours after dose, quinidine gluconate: four hours after dose; trough: immediately prior to next dose; after change in dose: one to two days.
Storage Instructions
Room temperature
Causes for Rejection
Gel-barrier tube; severe hemolysis; lipemia; icteric specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
